Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new nucleoside analogue.

GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies - 1 Jun 1995

Torres G

Abstract excerpt

The now-merged Glaxo/Burroughs-Wellcome has developed an experimental nucleoside analogue that has just entered clinical trials in Europe and the United States. The analogue, known as 1592U89 or just U89, is a defective version of the natural nucleoside guanine. It interferes with action of the HIV enzyme reverse transcriptase and prevents the infection of new cells by the virus. The company has just launched a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to AIDS Dementia Complex
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to Nucleosides

Share to RNA-Directed DNA Polymerase

Share to Zidovudine

Source

Identifiers

PMID: 11362687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new nucleoside analogue.PMID 11362687Read ↗

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus InfectionsSemantic proximity Read ↗

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseasesSemantic proximity Read ↗

Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.Semantic proximity Read ↗

The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.Semantic proximity Read ↗

Nucleoside analogues for the treatment of coronavirus infectionsSemantic proximity Read ↗

2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variantsSemantic proximity Read ↗

Structural and Biological Evaluations of a Non-Nucleoside STING Agonist Specific for Human STING <sup>A230</sup> VariantsSemantic proximity Read ↗

4’-fluorouridine as a potential COVID-19 oral drug?: a reviewSemantic proximity Read ↗

Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.Semantic proximity Read ↗

Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosidesSemantic proximity Read ↗

Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.Semantic proximity Read ↗

Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.